Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$22.83 USD
+0.25 (1.11%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $22.67 -0.16 (-0.70%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JANX 22.83 +0.25(1.11%)
Will JANX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JANX
JANX Stock Hits Record High on Prostate Cancer Study Data
Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last?
JANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for JANX
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
Decoding Janux Therapeutics Inc (JANX): A Strategic SWOT Insight
Janux Therapeutics GAAP EPS of -$0.55
Janux Therapeutics reports Q2 EPS (55c), consensus (47c)
Janux Therapeutics Inc (JANX) Announces First Patient Dosed in Merck Collaboration | JANX stock news